Recordati (REC.MI)

Executive Summary

Recordati is a century-old Italian pharmaceutical company with a strong focus on rare diseases and specialty pharmaceuticals. With over 4,450 employees and a market valuation of ~$12 billion, the company has established a robust commercial portfolio of 10 FDA-approved products and a pipeline targeting niche indications such as Cushing's syndrome, Schwannomatosis, and metabolic disorders. The company's core growth driver is Isturisa (osilodrostat), an approved treatment for Cushing's disease, which is now being investigated for mild autonomous cortisol secretion (MACS)—a potential label expansion opportunity. Recordati also has a Phase 2 trial for siltuximab in combination with erenumab for Schwannomatosis, addressing a high unmet need in chronic pain. With a disciplined M&A strategy and a century of operational excellence, Recordati is well-positioned for steady growth, though near-term catalysts are moderate and tied to clinical data readouts.

Upcoming Catalysts (preview)

• H1 2028Osilodrostat (Isturisa) Phase 3 trial in Mild Autonomous Cortisol Secretion (MACS) data60% success
• H2 2027Siltuximab + Erenumab Phase 2 trial in Schwannomatosis top-line results50% success